Products for Research Use Only

Cinrebafusp alfa

CAT: 0804-HY-P99605-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99605-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM) . Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research[1][2].
CAS Number
2218515-90-1
Product Name Alternative
PRS 343
UNSPSC
12352203
Target
EGFR; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cinrebafusp-alfa.html
Purity
98.53
Solubility
H2O
Smiles
[Cinrebafuspalfa]
Molecular Weight
(187.87 kDa)
References & Citations
[1]Marlon J Hinner, et al. Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343. Clin Cancer Res. 2019 Oct 1;25 (19) :5878-5889.|[2]G. Ku, et al. 525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies. ABSTRACT ONLY, VOLUME 31, SUPPLEMENT 4, S462-S463, SEPTEMBER 01, 2020.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Isoform
ErbB2/HER2; TNFRSF9/4-1BB/CD137